Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Bioimpedance as a measure of fluid status in critically ill patients: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Treatment Response Biomarkers in Asthma and COPD

    Research output: Contribution to journalReviewResearchpeer-review

  3. Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 infection: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Corticosteroid Resistance in Smokers-A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Do we need biomarkers of lung damage and infection: For what purpose and how should they be used properly? Biomarkers of lung damage can be used for diagnosis, risk stratification/prediction, treatment surveillance and adjustment of targeted therapy. Additionally, novel "omics" methods may offer a completely different and effective way of improving the understanding of pathogenesis of lung damage and a way to develop new candidate lung damage biomarkers. In the current review, we give an overview within the field of acute lung damage of (i) disease mechanism biomarkers, (ii) of "ready to use" evidence-based biomarker-guided lung infection management, (iii) of novel strategies of inflammatory phenotyping and how this can be used to tailor corticosteroid treatment, (iv) a future perspective of where "omics" technologies and mindsets may become increasingly important in developing new strategies for treatment and for understanding the development of acute lung damage.

Original languageEnglish
JournalJournal of Clinical Medicine
Volume8
Issue number8
ISSN2077-0383
DOIs
Publication statusPublished - 3 Aug 2019

ID: 59437220